You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
79 search results for: expert insights
expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?
Pulmonology
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.
The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD
Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.
Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
Dermatology
Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.